As discussed further up this thread, the human dose of SLU-PP-332, if based on the mouse results, would be extremely high.
Since there have not been any human clinical studies that demonstrate effective clinical dosing, I’m still not sure that such a low dose, as is being promoted by the bro-science guys, is going to be truly effective. They have no clinical evidence to back up their claims. As in Zero evidence but lots of anecdotal.
Anecdotal can be helpful, as we have had some reports of improvements in various functions but that’s not what I’d call definitive.
In mice the dose was high, up to 50 mg/kg twice per day and as “low” as 25 mg/kg twice per day PLUS it was administered as an intraperitoneal injection (not orally) to get the results in the mouse trials.
To convert that mouse dose to a human dose multiply by 0.081 = 4 mg per kg.
I weigh 64kg x 4mg = 265 mg injected daily for 28 days to duplicate the mouse dose and duration in the study. High dose and a significantly more effective deliver method than orally.
So I really do not understand how taking 1/1000 of the dose orally (vs injected) would have the same effect on humans.
256mg / 1000 = 0.256mg = 256mcg
While many are reporting benefits at this dose, there is no control, there is no testing and no structure to this process but there is a huge profit potential at that low dose.
Having said that, I think I’m going to try some high dose oral testing on my fav guinea pig.
Even the developers recognize that injection is currently superior to oral and they are working on a new version to make it more effective as an oral product vs injection.
The next step in developing SLU-PP-332 into a drug candidate will be to refine its structure, ideally making it available as a pill instead of an injection. Then the drug would be tested for side effects in more animal models before making the jump to human trials.